

Terminal Complement Complex ELISA



The complement system plays an essential role in acute and chronic inflammation, in immune response to infections, and in autoimmune disease. Terminal Complement Complex (TCC) is a well-published marker for complement studies in basic and translational research, clinical evaluation of treatment, and safety studies for medical devices and drugs.

The Complement System TCC ELISA is quick and easy-to-use for the determination of TCC (also known as sC5b-9) in human plasma. TCC is produced when any of the three complement pathways is activated. Measuring TCC is useful whenever complement system activation is possible or suspected, as it gives an overall view of activity independent of pathway.

Complement System TCC ELISA

Catalog # 13-COMPL-TCC
Sensitivity: 3 ng/mL
Range: 10 - 400 ng/mL
Sample: EDTA Plasma
Detection: Colorimetric


For Research Use Only. Not for use in diagnostic procedures.

Key Features:

- **Broadly Applicable** -TCC is a universal complement activity marker independent of activation pathway.
- **Easy-to-Use** - The TCC ELISA includes ready-to-use reagents and a short incubation that simplifies workflow.
- **Proven Track Record** -TCC has been trusted for 30+ years as a complement activity biomarker in research and drug development.

TCC's Role in Research and Drug Development

Studies have shown that the complement system plays a key role in the development and amplification of the inflammatory process at the tissue level in various pathological conditions. For example, elevated levels of TCC can be detected in hemolytic uremic syndrome (HUS), Systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).^{1,2,3,4} The complement system can also be activated by artificial surfaces, for example during hemodialysis or cardiopulmonary bypass, resulting in increased levels of TCC.^{5,6} TCC is also well-suited to study potential complement activation from biomaterials in medical devices.⁷



TCC can be generated from all three complement pathways.



Complement System Immunoassay Portfolio

ALPCO offers a portfolio of ELISAs, manufactured by Svar Life Science AB, to explore every angle of complement system involvement. Individual ELISAs to measure activation of the Classical, Lectin/MBL, and Alternative Pathways are available along with a Total Functional Screen measuring all pathways on a single plate. ELISAs to detect specific activity biomarkers like C4d and Terminal Complement Complex (TCC) are also available. To learn more, visit www.alpco.com/complement-system.

Related Products

Item	Catalog Number
Classical Pathway ELISA	13-COMPL-CP310
Alternative Pathway ELISA	13-COMPL-AP330
Lectin/MBL Pathway ELISA	13-COMPL-MP320
Total Complement Functional Screen ELISA	13-COMPL-300
Complement C4d ELISA	13-COMPL-C4d
Terminal Complement Complex (TCC) ELISA	13-COMPL-TCC
Anti-C4d Antibody	04-BI-RC4D
Anti human C4d (FITC Conjugated)	04-BI-RC4D-FITC

For Research Use Only. Not for use in diagnostic procedures.

References:

- Noris, M. et al. 2012. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 8, 622–633. DOI: 10.1038/nrneph.2012.195
- Porcel et al. 1995. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol. Mar;74(3):283-8. PMID: 7859418
- Mollnes et al. 1999. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology (Oxford). Oct;38(10):933-40. <https://doi.org/10.1093/rheumatology/38.10.933>
- Struglics et al. 2016. The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis. Arthritis Res Ther. Oct 6;18(1):223. DOI:10.1186/s13075-016-1123-x
- Deppisch et al. 1990. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int. Feb;37(2):696-706. DOI: 10.1038/ki.1990.36
- Ovrum et al. 1996. Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation. Eur J Cardiothorac Surg.;10(1):54-60. DOI: 10.1016/s1010-7940(96)80266-1
- Stang et al. 2014. Hemocompatibility testing according to ISO 10993-4: discrimination between pyrogen- and device-induced hemostatic activation. Mater Sci Eng C Mater Biol Appl. Sep;42:422-8. DOI: 10.1016/j.msec.2014.05.070



www.stratech.co.uk
+44 (0) 1638 782600
orders@stratech.co.uk

free delivery
for uk
universities



we offer a
full product
guarantee



outstanding
technical
support



 @stratech_uk
 @stratechscientificltd
 @stratech-scientific-ltd

